Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, Curcio H, Du Rusquec P, Cortot AB, Gounant V, Abbar B, Duchemann B, Giroux-Leprieur E, Pierret T, Quilot FM, Cadranel J, Fallet V. Mehlman C, et al. Among authors: swalduz a. Oncologist. 2024 Dec 26:oyae312. doi: 10.1093/oncolo/oyae312. Online ahead of print. Oncologist. 2024. PMID: 39724403 Free article.
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot JM, Duruisseaux M, Fournel P, Odier L, Demolombe S, Bizieux-Thaminy A, Peytier A, Schott R, Hominal S, Tissot C, Bombaron P, Metzger S, Donnat M, Ortiz-Cuaran S, Rosenfeld N, Pipinikas C, Saintigny P, Pérol M. Swalduz A, et al. J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530-9. doi: 10.1016/j.jtho.2024.12.011. Online ahead of print. J Thorac Oncol. 2024. PMID: 39694415 Free article.
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB. Swalduz A, et al. Lung Cancer. 2024 Nov 26;199:108038. doi: 10.1016/j.lungcan.2024.108038. Online ahead of print. Lung Cancer. 2024. PMID: 39616778
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.
Girard N, Guisier F, Swalduz A, Van Hulst S, Pichon E, Lavaud P, Greillier L, Tiotiu A, Madroszyk A, Bylicki O, Canellas A, Belmont L, Zysman M, Hauss PA, Godbert B, Audigier-Valette C, Lebreton C, Morin F, Westeel V. Girard N, et al. Among authors: swalduz a. ESMO Open. 2024 Dec;9(12):103968. doi: 10.1016/j.esmoop.2024.103968. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608302 Free PMC article.
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB. Ferreira M, et al. Among authors: swalduz a. Lung Cancer. 2024 Oct;196:107934. doi: 10.1016/j.lungcan.2024.107934. Epub 2024 Aug 24. Lung Cancer. 2024. PMID: 39277916 Clinical Trial.
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. Lin JJ, et al. Among authors: swalduz a. Cancer Discov. 2024 Dec 2;14(12):2367-2386. doi: 10.1158/2159-8290.CD-24-0231. Cancer Discov. 2024. PMID: 39269178 Free PMC article. Clinical Trial.
Treatment sequences in EGFR mutant advanced NSCLC.
Wespiser M, Swalduz A, Pérol M. Wespiser M, et al. Among authors: swalduz a. Lung Cancer. 2024 Aug;194:107895. doi: 10.1016/j.lungcan.2024.107895. Epub 2024 Jul 17. Lung Cancer. 2024. PMID: 39047615 Review.
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, Bernardi M, Hominal S, Prevost JB, Pamart G, Marques MH, Cloarec N, Deshayes S, Raimbourg J, Veillon R, Oulkhouir Y, Audigier Valette C, Subtil F, Chouaïd C, Greillier L; GFPC. Bylicki O, et al. Among authors: swalduz a. Lung Cancer. 2024 Aug;194:107866. doi: 10.1016/j.lungcan.2024.107866. Epub 2024 Jun 29. Lung Cancer. 2024. PMID: 38972083 Free article.
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Peters S, et al. Among authors: swalduz a. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. Nat Med. 2024. PMID: 38898120 Free PMC article. Clinical Trial.
50 results